Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (51-60 of 272) with videos related to

Pageof 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 9, 2007
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancerSanjay Popat, Yolanda Barbachano, Sue Ashley, et al.
BMC Cancer|April 18, 2015
Resolution of severe hyponatraemia is associated with improved survival in patients with cancerKirsty Balachandran, Alicia Okines, Ranga Gunapala, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancerRaffaele Califano, Alastair Greystoke, Rohit Lal, et al.
Future Oncology (London, England)|March 23, 2017
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic optionsSanjay Popat, Anders Mellemgaard, Martin Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2021
Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - Systematic review and meta-analysisBartłomiej Tomasik, Michał Bieńkowski, Marcin Braun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2025
Missed Opportunity for Sotorasib Dose OptimizationGarth W Strohbehn, Jill Feldman, Sanjay Popat, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2022
Targeting un-MET needs in advanced non-small cell lung cancerNiamh Coleman, Alice Harbery, Sara Heuss, et al.
JTO Clinical and Research Reports|September 30, 2021
Severe Immune Checkpoint Inhibitor Hepatitis in <i>KRAS</i> G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case ReportParvin Begum, Robert D Goldin, Lucia A Possamai, et al.
Journal of Comparative Effectiveness Research|February 25, 2022
Health technology assessments and real-world evidence: tell us what you want, what you really, really wantFrank Griesinger, Oliver Cox, Cormac Sammon, et al.
Nature Reviews. Cancer|July 26, 2017
Novel insights into mesothelioma biology and implications for therapyTimothy A Yap, Joachim G Aerts, Sanjay Popat, et al.
Pageof 28

Showing results (51-60 of 272) with videos related to

Sort By:
Pageof 28
Lung Cancer (Amsterdam, Netherlands)|October 9, 2007
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancerSanjay Popat, Yolanda Barbachano, Sue Ashley, et al.
BMC Cancer|April 18, 2015
Resolution of severe hyponatraemia is associated with improved survival in patients with cancerKirsty Balachandran, Alicia Okines, Ranga Gunapala, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancerRaffaele Califano, Alastair Greystoke, Rohit Lal, et al.
Future Oncology (London, England)|March 23, 2017
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic optionsSanjay Popat, Anders Mellemgaard, Martin Reck, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2021
Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score ≥2 - Systematic review and meta-analysisBartłomiej Tomasik, Michał Bieńkowski, Marcin Braun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2025
Missed Opportunity for Sotorasib Dose OptimizationGarth W Strohbehn, Jill Feldman, Sanjay Popat, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2022
Targeting un-MET needs in advanced non-small cell lung cancerNiamh Coleman, Alice Harbery, Sara Heuss, et al.
JTO Clinical and Research Reports|September 30, 2021
Severe Immune Checkpoint Inhibitor Hepatitis in <i>KRAS</i> G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case ReportParvin Begum, Robert D Goldin, Lucia A Possamai, et al.
Journal of Comparative Effectiveness Research|February 25, 2022
Health technology assessments and real-world evidence: tell us what you want, what you really, really wantFrank Griesinger, Oliver Cox, Cormac Sammon, et al.
Nature Reviews. Cancer|July 26, 2017
Novel insights into mesothelioma biology and implications for therapyTimothy A Yap, Joachim G Aerts, Sanjay Popat, et al.
Pageof 28